Showing 1511-1520 of 3020 results for "".
- Sensus Healthcare Receives Frost & Sullivan 2016 Global NMSC Therapy Technology Leadership Awardhttps://practicaldermatology.com/news/sensus-healthcare-inc-receives-frost-sullivan-2016-global-nmsc-therapy-technology-leadership-award/2458443/Sensus Healthcare, Inc. has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Tec
- IV Glutathione for Skin Whitening is Risky Business, UK Doctor Warnshttps://practicaldermatology.com/news/iv-glutathione-for-skin-whitening-is-risky-business-uk-doctor-warns/2458444/Skin bleaching with IV glutathione is on the rise, despite potential risks, warns a doctor in The BMJ. Both the US Food and Drug Administration (FDA) and the Dermatology Society in the Philippines -- where the practice i
- Freedom Laser Therapy Launches iRESTORE Hair Growth Systemhttps://practicaldermatology.com/news/freedom-laser-therapy-launches-irestore-hair-growth-system/2458457/Freedom Laser Therapy is rolling out the iRestore Hair Growth System. The hands-free iRestore Hair Growth System is US Food and Drug Administr
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to t
- Skin Cancer Foundation Calls for Grant Proposals for the 2017 Research Grant Awards Programhttps://practicaldermatology.com/news/skin-cancer-foundation-calls-for-grant-proposals-for-the-2017-research-grant-awards-program/2458466/The Skin Cancer Foundation is calling for grant proposals for their 2017 Research Grant Awards Program. Four grants of $25,000 will be awarded to research projects and clinical studies related t
- Men, New Technologies Drive Growth in Body Contouring Markethttps://practicaldermatology.com/news/men-new-technologies-drive-growth-in-body-contouring-market/2458467/The body contouring market is set to rise from $671.8 million in 2015 to more than $1.1 billion by 2022, representing a compound annual growth rate of 7.9%, according to research and consulting firm
- Deadline Approaching: Apply for Grant from La Roche-Posay's "Dermatologist from the Heart" Programhttps://practicaldermatology.com/news/deadline-approaching-apply-for-grant-from-la-roche-posays-dermatologist-from-the-heart-program/2458476/La Roche-Posay plans to continue its "Dermatologist from the Heart" program for the fifth year. As part of the program, La Roche-Posay provides grant money up to $10,000 to fund community-oriented projects that ma
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien